Gene transfer for inherited metabolic disorders of the liver: Immunological challenges

Current Pharmaceutical Design

Volumn 17, Issue 24, 2011, Pages 2542-2549

  Gordts, Stephanie C ^a   van Craeyveld, Eline ^a   Jacobs, Frank ^a   de Geest, Bart ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Adaptive immunity; Gene therapy; Gene transfer; Innate immunity; Liver; Tolerance

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; LIVER ANTIGEN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; FETAL THERAPY; GENE CASSETTE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOLOGICAL TOLERANCE; INBORN ERROR OF METABOLISM; INNATE IMMUNITY; LIVER CELL; LIVER DISEASE; LYMPH NODE; LYMPHOID TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROENVIRONMENT; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; THYMUS; TRANSGENE;

ADAPTIVE IMMUNITY; ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATOCYTES; HUMANS; IMMUNITY, INNATE; LIVER DISEASES; METABOLISM, INBORN ERRORS; SPECIES SPECIFICITY; TRANSGENES;

EID: 80053483386     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797247604     Document Type: Article

References (81)

1. Jacobs F, Feng Y, Van Craeyveld E, et al. Species differences in hepatocyte-directed gene transfer: implications for clinical translation. Curr Gene Ther 2009; 9: 83-90.
2. Jacobs F, Wisse E, and De Geest B. The role of liver sinusoidal cells in hepatocyte-directed gene transfer. Am J Pathol 2010; 176: 14-21.
3. Van Craeyveld E, Gordts S, Jacobs F, and De Geest B. Gene therapy to improve high-density lipoprotein metabolism and function. Curr Pharm Des 2010; 16: 1531-44.
4. Liu F, Song Y, and Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-66.
5. Zhang G, Budker V, and Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-7.
6. Jacobs F, Snoeys J, Feng Y, et al. Direct comparison of hepatocytespecific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer. Gene Ther 2008; 15: 594-603.
7. Eastman SJ, Baskin KM, Hodges BL, et al. Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Hum Gene Ther 2002; 13: 2065-77.
8. Yoshino H, Hashizume K, and Kobayashi E. Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume. Gene Ther 2006; 13: 1696-702.
9. Fabre JW, Grehan A, Whitehorne M, et al. Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava. Gene therapy 2008; 15: 452-62.
10. Mays LE and Wilson JM. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther 2011; 19: 16-27.
11. Zaldumbide A and Hoeben RC. How not to be seen: immuneevasion strategies in gene therapy. Gene Ther 2008; 15: 239-46.
12. Zaiss AK and Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008; 15: 808-16.
13. Nayak S and Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010; 17: 295-304.
14. Lievens J, Snoeys J, Vekemans K, et al. The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther 2004; 11: 1523-31.
15. Snoeys J, Lievens J, Wisse E, et al. Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther 2007; 14: 604-12.
16. Wisse E, Jacobs F, Topal B, Frederik P, and De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther 2008; 15: 1193-9.
17. Wisse E, Braet F, Duimel H, et al. Fixation methods for electron microscopy of human and other liver. World J Gastroenterol 2010; 16: 2851-66.
18. Lieber A, He CY, Meuse L, et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71: 8798-807.
19. Muruve DA, Barnes MJ, Stillman IE, and Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-76.
20. Wolff G, Worgall S, van Rooijen N, et al. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71: 624-9.
21. Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3: 697-707.
22. Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3: 708-22.
23. Zaiss AK, Liu Q, Bowen GP, et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76: 4580-90.
24. Liu Q, Zaiss AK, Colarusso P, et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 2003; 14: 627-43.
25. Nunes FA, Furth EE, Wilson JM, and Raper SE. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther 1999; 10: 2515-26.
26. Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163-75.
27. Kobayashi S, Nagino M, Yokoyama Y, Nimura Y, and Sokabe M. Evaluation of hepatic interleukin-6 secretion following portal vein ligation using a minimal surgical stress model. J Surg Res 2006; 135: 27-33.
28. De Geest B, Snoeys J, Van Linthout S, Lievens J, and Collen D. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum Gene Ther 2005; 16: 1439-51.
29. Appledorn DM, Patial S, McBride A, et al. Adenovirus vectorinduced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 2008; 181: 2134-44.
30. Zhong B, Ma HY, Yang Q, et al. Decrease in toll-like receptors 2 and 4 in the spleen of mouse with endotoxic tolerance. Inflamm Res 2008; 57: 252-9.
31. Martin-Armas M, Simon-Santamaria J, Pettersen I, et al. Toll-like receptor 9 (TLR9) is present in murine liver sinusoidal endothelial cells (LSECs) and mediates the effect of CpG-oligonucleotides. J Hepatol 2006; 44: 939-46.
32. Equils O, Schito ML, Karahashi H, et al. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J Immunol 2003; 170: 5159-64.
33. Snoeys J, Mertens G, Lievens J, et al. Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer. Mol Ther 2006; 13: 98-107.
34. Croyle MA, Le HT, Linse KD, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 2005; 12: 579-87.
35. Gao G, Lu Y, Calcedo R, et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006; 13: 77-87.
36. Zhu J, Huang X, and Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009; 119: 2388-98.
37. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007; 13: 419-22.
38. De Geest B, Van Linthout S, and Collen D. Sustained expression of human apo A-I following adenoviral gene transfer in mice. Gene Ther 2001; 8: 121-7.
39. De Geest BR, Van Linthout SA, and Collen D. Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigenpresenting cells. Blood 2003; 101: 2551-6.
40. Feng Y, Jacobs F, Van Craeyveld E, et al. The impact of antigen expression in antigen-presenting cells on humoral immune responses against the transgene product. Gene Ther 2010; 17: 288-93.
41. Van Linthout S, Spillmann F, Riad A, et al. Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation 2008; 117: 1563-73.
42. Van Craeyveld E, Lievens J, Jacobs F, et al. Apolipoprotein A-I and lecithin:cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions. Gene Ther 2009; 16: 757-65.
43. Stockinger B. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv Immunol 1999; 71: 229-65.
44. Farr AG, Dooley JL, and Erickson M. Organization of thymic medullary epithelial heterogeneity: implications for mechanisms of epithelial differentiation. Immunol Rev 2002; 189: 20-7.
45. Watanabe N, Wang YH, Lee HK, et al. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005; 436: 1181-5.
46. Watanabe N, Hanabuchi S, Soumelis V, et al. Human thymic stromal lymphopoietin promotes dendritic cell-mediated CD4+ T cell homeostatic expansion. Nat Immunol 2004; 5: 426-34.
47. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3: 673-80.
48. Haley PJ. Species differences in the structure and function of the immune system. Toxicology 2003; 188: 49-71.
49. Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol 2006; 34: 455-65.
50. Ohtani O and Ohtani Y. Lymph circulation in the liver. Anat Rec (Hoboken) 2008; 291: 643-52.
51. Dunn TB. Normal and pathologic anatomy of the reticular tissue in laboratory mice, with a classification and discussion of neoplasms. J Natl Cancer Inst 1954; 14: 1281-433.
52. Thomson AW and Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010; 10: 753-66.
53. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223: 472-6.
54. Bamboat ZM, Stableford JA, Plitas G, et al. Human liver dendritic cells promote T cell hyporesponsiveness. J Immunol 2009; 182: 1901-11.
55. Thomson AW and Lu L. Are dendritic cells the key to liver transplant tolerance? Immunol Today 1999; 20: 27-32.
56. Li G, Kim YJ, and Broxmeyer HE. Macrophage colony-stimulating factor drives cord blood monocyte differentiation into IL-10(high)IL-12absent dendritic cells with tolerogenic potential. J Immunol 2005; 174: 4706-17.
57. Rutella S, Bonanno G, Procoli A, et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 2006; 108: 218-27.
58. Warren A, Le Couteur DG, Fraser R, et al. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology 2006; 44: 1182-90.
59. Bertolino P, Trescol-Biemont MC, and Rabourdin-Combe C. Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur J Immunol 1998; 28: 221-36.
60. Bowen DG, Zen M, Holz L, et al. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest 2004; 114: 701-12.
61. Nathwani AC, Davidoff A, Hanawa H, et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 2001; 97: 1258-65.
62. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99: 2670-6.
63. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111: 1347-56.
64. Follenzi A, Battaglia M, Lombardo A, et al. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2004; 103: 3700-9.
65. Pastore L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999; 10: 1773-81.
66. De Geest B, Van Linthout S, Lox M, Collen D, and Holvoet P. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum Gene Ther 2000; 11: 101-12.
67. Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin Immunol 2000; 12: 163-71; discussion 257-344.
68. Zinkernagel RM. What is missing in immunology to understand immunity? Nat Immunol 2000; 1: 181-5.
69. Calin-Laurens V, Forquet F, Lombard-Platet S, et al. High efficiency of endogenous antigen presentation by MHC class II molecules. Int Immunol 1992; 4: 1113-21.
70. Muller A, Schott-Ohly P, Dohle C, and Gleichmann H. Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin. Immunobiology 2002; 205: 35-50.
71. Chao H, Mao L, Bruce AT, and Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 2000; 95: 1594-9.
72. Scallan CD, Lillicrap D, Jiang H, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood 2003; 102: 2031-7.
73. Chuah MK, Schiedner G, Thorrez L, et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 2003; 101: 1734-43.
74. Porada CD, Park P, Almeida-Porada G, and Zanjani ED. The sheep model of in utero gene therapy. Fetal Diagn Ther 2004; 19: 23-30.
75. Waddington SN, Buckley SM, David AL, et al. Fetal gene transfer. Curr Opin Mol Ther 2007; 9: 432-8.
76. Colletti E, Lindstedt S, Park PJ, Almeida-Porada G, and Porada CD. Early fetal gene delivery utilizes both central and peripheral mechanisms of tolerance induction. Exp Hematol 2008; 36: 816-22.
77. Tran ND, Porada CD, Almeida-Porada G, et al. Induction of stable prenatal tolerance to beta-galactosidase by in utero gene transfer into preimmune sheep fetuses. Blood 2001; 97: 3417-23.
78. Trombetta ES and Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005; 23: 975-1028.
79. Dani A, Chaudhry A, Mukherjee P, et al. The pathway for MHCIImediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment. J Cell Sci 2004; 117: 4219-30.
80. Brown BD, Cantore A, Annoni A, et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007; 110: 4144-52.
81. Van Linthout S, Lusky M, Collen D, and De Geest B. Persistent hepatic expression of human apo A-I after transfer with a helpervirus independent adenoviral vector. Gene Ther 2002; 9: 1520-8.